## New ICD-10-CM/PCS COVID-19 codes, effective Jan. 1, 2021

ICD-10-PCS (inpatient procedure) codes

| Procedure code | Description |
| :---: | :---: |
| XW013H6 | Introduction of other new technology monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6 |
| XW013K6 | Introduction of leronlimab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6 |
| XW013S6 | Introduction of COVID-19 vaccine dose 1 into subcutaneous tissue, percutaneous approach, new technology group 6 |
| XW013T6 | Introduction of COVID-19 vaccine dose 2 into subcutaneous tissue, percutaneous approach, new technology group 6 |
| XW013U6 | Introduction of COVID-19 vaccine into subcutaneous tissue, percutaneous approach, new technology group 6 |
| XW023S6 | Introduction of COVID-19 vaccine dose 1 into muscle, percutaneous approach, new technology group 6 |
| XW023T6 | Introduction of COVID-19 vaccine dose 2 into muscle, percutaneous approach, new technology group 6 |
| XW023U6 | Introduction of COVID-19 vaccine into muscle, percutaneous approach, new technology group 6 |
| XW033E6 | Introduction of etesevimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6 |
| XW033F6 | Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6 |
| XW033G6 | Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6 |
| XW033H6 | Introduction of other new technology monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6 |
| XW033L6 | Introduction of CD24Fc immunomodulator into peripheral vein, percutaneous approach, new technology group 6 |
| XW043E6 | Introduction of etesevimab monoclonal antibody into central vein, percutaneous approach, new technology group 6 |


| Procedure <br> code | Description |
| :--- | :--- |
| XW043F6 | Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous <br> approach, new technology group 6 |
| XW043G6 | Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous <br> approach, new technology group 6 |
| XW043H6 | Introduction of other new technology monoclonal antibody into central vein, <br> percutaneous approach, new technology group 6 |
| XW043L6 | Introduction of CD24Fc immunomodulator into central vein, percutaneous approach, <br> new technology group 6 |
| XW0DXM6 | Introduction of baricitinib into mouth and pharynx, external approach, new technology <br> group 6 |
| XW0G7M6 | Introduction of baricitinib into upper GI, via natural or artificial opening, new technology <br> group 6 |
| XW0H7M6 | Introduction of baricitinib into lower GI, via natural or artificial opening, new technology <br> group 6 |

ICD-10-CM (diagnosis) codes

| Diagnosis <br> codes | Description |
| :--- | :--- |
| J1282 | Pneumonia due to coronavirus disease 2019 |
| M3581 | Multisystem inflammatory syndrome CC |
| M3589 | Other specified systemic involvement of connective tissue |
| Z1152 | Encounter for screening for COVID-19 |
| Z20822 | Contact with and (suspected) exposure to COVID19 |
| Z8616 | Personal history of COVID-19 |

